gimeracil,tegafur,nivolumab,capecitabine,oxaliplatin,oteracil
otsuka,bms,nordic group,ono pharma
['nivolumab', 'nivo', 'esophageal', 'gastroesophageal', 'attraction-5', 'gastric']
disappointing results of attraction-5. adjuvant nivolumab plus chemotherapy vs placebo plus chemo for pathological stage iii (pstage iii) gastric or gastroesophageal junction (g/gej) cancer. #asco23 #asco2023 #asco 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"